Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyAlaska Medicaid opioid duplication edits Coverage …
    Ask Trek AI about this page
    CurrentAlaska MedicaidPolicy N/A

    Opioid Therapeutic Duplication Edits

    Customize your policy alerts

    Sign up for all Alaska Medicaid policy alerts

    Know when Alaska Medicaid releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document explains Alaska Medicaid's implementation of automated therapeutic duplication edits for opioid analgesics, describing which products/categories trigger denials, the 19-day look-back window, override/prior authorization options, and point-of-sale override codes. It affects Alaska Medicaid recipients, prescribers, and pharmacies.

    Policy Summary
    PayerAlaska Medicaid
    PolicyOpioid Therapeutic Duplication Edits
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 14, 2012
    Next Review DateN/A
    Key ActionIf rejection is due to a dosing or therapy change and the prescriber is the same prescriber or prescriber group, the pharmacy may request an override by contacting the Magellan Clinical Call Center at (800) 331-4475.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    19-daylook-back period for duplication edits
    same categoryedits only apply to medications in the same opioid category
    special rule

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Suboxone/Subutex special rule
    Magellan Call Centeroverride/prior authorization contact
    NCPDP fieldspoint-of-sale override codes

    Therapeutic Duplication Coverage Rules

    Therapeutic duplication coverage criteria and exceptions

    Alaska Medicaid will deny claims that represent therapeutic duplication of opioids according to category and listed equivalencies; exceptions and overrides are available.

    Edits apply to opioid medications dispensed within a 19-day look-back period and only to products within the same category (medications and categories listed in the document).

    Same-category duplication

    • Multiple claims for similar products within the same category during the 19-day look-back will be denied (example: Morphine JR and Oxycodone JR would trigger the edit).
    • Products from different categories will not trigger the edit (example: Hydrocodone/APAP and Morphine ER would not trigger the edit).

    Suboxone/Subutex special rule

    • If a recipient has a claim for Suboxone or Subutex within the last 19 days, all opioid claims will reject regardless of category.
    • To request an override for a Suboxone/Subutex-related rejection the prescriber must contact the Magellan Clinical Call Center at (800) 331-4475.
    • If an override is obtained for Suboxone/Subutex, any existing prior authorization for Suboxone or Subutex will be ended.

    Overrides for dosing or therapy changes

    • If rejection is due to a dosing or therapy change and the prescription is written by the same prescriber or prescriber group, the pharmacy may request an override by contacting the Magellan Clinical Call Center at (800) 331-4475.
    • If rejection is due to a dosing or therapy change and the prescription is from a different prescriber or prescriber group, the prescriber may request an override by contacting the Magellan Clinical Call Center at (800) 331-4475 or by faxing a prior authorization request form to (888) 603-7696.
    Point-of-sale overrides: Designated point-of-sale override codes may be used by the pharmacy for specified situations without contacting the Magellan Clinical Call Center (see coding/point-of-sale instructions).

    Opioid Product Equivalencies and Look-back

    Combination / Strength Equivalenciesmixed
    Codeine/APAP (combo)mapped equivalent: Oxycodone/ASA
    Codeine/ASA (combo)mapped equivalent: Oxycodone/ASA
    Hydrocodone/APAP (combo)mapped equivalent: Propoxyphene/APAP
    Hydrocodone/ASA (combo)mapped equivalent: Pentazocine/Naloxone
    Ibuprofen/Hydrocodone (combo)mapped equivalent: Ibuprofen/Oxycodone
    Oxycodone/APAP (combo)mapped equivalent: Butorphanol Nasal Spray
    Codeine 15 mg tabmapped equivalent: Hydromorphone 1 mg/mL
    Codeine 30 mg tabmapped equivalent: Methadone 5 mg/5 mL
    Codeine 60 mg tabmapped equivalent: Methadone 10 mg/5 mL
    Codeine 15 mg tab solmapped equivalent: Methadone 10 mg/mL
    1–10 of 68
    1/7
    Look-back Period
    Therapeutic duplication look-back period19 days

    Overrides, Prior Authorization, and Point-of-Sale Codes

    Prior Authorization

    Override and prior authorization process

    If a claim is rejected because of a dosing or therapy change: - If the prescription is written by the same prescriber or prescriber group as the previous claim(s), the pharmacy may request an override by contacting the Magellan Clinical Call Center at (800) 331-4475. - If the prescription is from a different prescriber or prescriber group, the prescriber may request an override by contacting the Magellan Clinical Call Center at (800) 331-4475 or by faxing a prior authorization request form to the Magellan Clinical Call Center at 888-603-7696. If a recipient has a claim for Suboxone or Subutex within the last 19 days, all opioid claims will reject and the prescriber must contact the Magellan Clinical Call Center at (800) 331-4475 to request an override; if an override is obtained any existing prior authorization for Suboxone or Subutex will be ended.

    • Pharmacy override option when same prescriber or prescriber group: Magellan Clinical Call Center (800-331-4475).
    • Prescriber override option when different prescriber/prescriber group: Magellan Clinical Call Center (800-331-4475) or fax prior authorization form to 888-603-7696.
    • Special rule for Suboxone/Subutex within 19 days: prescriber must contact Magellan Clinical Call Center; existing PA will be ended if override obtained.

    Terminology and Category Groupings

    Automated claims processing edits
    DefinitionTherapeutic duplication edits are automated claims processing edits that deny multiple claims for similar opioid products when dispensed within a 19‑day look‑back period and within the same opioid category.
    Same‑category requirementEdits only apply when the products are in the same category; products in different categories are not considered duplicates (system coded by category).
    Override for dosing/therapy changesIf rejection is due to dosing or therapy change and prescription is from the same prescriber or prescriber group, the pharmacy may request an override via Magellan Clinical Call Center (800‑331‑4475).
    Override when different prescriberIf the prescription is from a different prescriber/prescriber group, the prescriber may request an override via Magellan Clinical Call Center or fax a prior authorization form to Magellan (888‑603‑7696).
    Categories and product mappings
    Policy Summary
    PayerAlaska Medicaid
    PolicyOpioid Therapeutic Duplication Edits
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 14, 2012
    Next Review DateN/A
    Key ActionIf rejection is due to a dosing or therapy change and the prescriber is the same prescriber or prescriber group, the pharmacy may request an override by contacting the Magellan Clinical Call Center at (800) 331-4475.
    SourceLink
    On This Page
    Therapeutic Duplication Coverage RulesOpioid Product Equivalencies and Look-backOverrides, Prior Authorization, and Point-of-Sale CodesTerminology and Category Groupings
    Billing Rule

    Point-of-sale override codes (NCPDP fields)

    Point-of-sale overrides may be submitted using specific NCPDP fields and values to bypass a therapeutic duplication rejection for certain settings: use Patient Residence (NCPDP field 384-4X) = '11' for hospice; Prior Authorization Type Code (NCPDP field 461-EU) = '2' for cancer treatment; Patient Residence (NCPDP field 384-4X) = '4' for long term care.

    • Patient Residence (NCPDP field 384-4X) = '11' — hospice
    • Prior Authorization Type Code (NCPDP field 461-EU) = '2' — cancer treatment
    • Patient Residence (NCPDP field 384-4X) = '4' — long term care
    Long‑acting product mappingsDocument lists one‑to‑one equivalencies mapping specific long‑acting products to equivalent extended‑release strengths (e.g., Subutex/Suboxone strengths mapped to Avinza; fentanyl patches mapped to Kadian equivalents; multiple methadone and morphine ER to oxycodone SR equivalents).
    Combination product groupingsCombination opioid products are mapped to equivalent single‑entity or other combination products (document contains numerous one‑to‑one equivalency mappings).
    Use for duplication determinationThese category groupings and specific product equivalencies are used by the claims system to determine which products are considered therapeutically equivalent for duplication edits.